SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
Amendment No. 1 to
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
August 31, 2011
Date of Report
(Date of Earliest Event Reported)
BIOPHARMA MANUFACTURING SOLUTIONS INC.
(Exact Name of Registrant as Specified in its Charter)
BEACHWOOD ACQUISITION CORPORATION
(Former Name of Registrant)
Delaware 000-54423 45-1878223
(State or other (Commission File Number) (IRS Employer
jurisdiction Identification No.)
of incorporation)
1443 Merion Way, #51G
Seal Beach, California 90740
(Address of Principal Executive Offices)
215 Apolena Avenue
Newport Beach, California 92662
(Former Address of Principal Executive Offices)
(562) 244-9785
_________________
(Registrant's Telephone Number)
This amendment is filed to correct Item 3.02 to state the
consideration paid for the securities issued.
ITEM 3.02 Unregistered Sales of Equity Securities
On August 31, 2011 the Registrant issued 3,000,000 shares of its
common stock at par ($.0001 par) for an aggregate of $300 pursuant to
Section 4(2) of the Securities Act of 1933 to Gary Riccio representing
66% of the total outstanding 4,500,000 shares of common stock:
ITEM 5.01 Changes in Control of Registrant
On August 31, 2011 the following events occurred which resulted in
a change of control of the Registrant:
1. The Registrant redeemed an aggregate of 18,500,000 of the then
20,000,000 shares of outstanding stock at a redemption price of $.0001
per share for an aggregate redemption price of $1,850.
2. New officers and directors were appointed and elected and the
prior officers and directors resigned.
The disclosure required by Item 5.01(a)(8) of Form 8-K was previously
filed with the Securities and Exchange Commission on Form 10-12G on June 2,
2011 as updated by the Quarterly Report on Form 10-Q filed August 19, 2011
and as supplemented by the information contained in this report.
The Registrant intends to provide engineering consulting services to
major biotech and pharmaceutical companies in the life sciences industry.
The Registrant intends to take its clients manufacturing goals from concept
to FDA approval and market realization. The Registrant will assist in the
design of the process used to manufacture the client's product, typically
pharmaceuticals, will procure and install the requisite manufacturing
equipment and will validate the process and ready the system for FDA
approval.
ITEM 5.02 Departure of Directors or Principal Officers; Election of
Directors
On August 31, 2011, James M. Cassidy resigned as the Registrant's
president, secretary and director.
On August 31, 2011, James McKillop resigned as the Registrant's vice
president and director.
On August 31, 2011, Gary Riccio was elected to the board of directors
of the Registrant and was appointed president and secretary of the
Registrant.
Gary Riccio, 57, serves as the sole director and officer of the
Registrant. Mr. Riccio obtained his Bachelor of Science Degree in Chemical
Engineering in 1978 from Northeastern University and was elected to the
Engineering Honor Society. From 1978 to 1986, Mr. Riccio was employed by
Lever Brothers Division of Unilever as Project Engineer specializing in
the Dove and Caress, Snuggle and Wisk product lines and specifically
worked on the expansion of those facilities and processes. From 1987
to 1989, Mr. Riccio worked as Project Engineer for Vision Engineering,
a software start-up company, on automation systems for companies within
the chemical process, food and beverage and pharmaceutical industries.
From 1989 to 1996, Mr. Riccio worked as General Manager of A-1
Refrigeration Company designing, installing and servicing custom large
volume ice-making equipment and industrial refrigeration systems.
During this period he was instrumental in increasing the product line
from two to seven different models and expanded sales to overseas markets.
In 1996, Mr. Riccio founded GMR Engineering, an engineering contracting
firm specializing in automated computer systems for the biotech/
pharmaceutical and food/beverage industries. He expanded this business
to include process design and engineering, process validation and custom
equipment manufacturing.
His recent significant accomplishments include (i) the 2006 the
installation, programming and validation of Millipore Ultrafilitration
Skids and Cold Water For Injection Generation, Storage and Distribution
for Albumin Processing Department at Baxter BioScience, which received
FDA approval in November 2006; (ii) the 2010 control system design,
programming, installation and validation of the Nanofiltration System
for AHF-M Department; and (iii) the 2010 custom design, fabrication,
automation and validation of the Nanofiltration System for Virus
Removal currently under review by the FDA for approval to begin
manufacturing.
ITEM 5.03 Amendments to Articles of Incorporation
On August 31, 2011, the shareholders of the Corporation and the
Board of Directors unanimously approved the change of the Registrant's
name to BioPharma Manufacturing Solutions Inc. and filed such change
with the State of Delaware.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunder duly authorized.
BIOPHARMA MANUFACTURING SOLUTIONS, INC.
formerly Beachwood Acquisition Corporation
Date: October 27, 2011 /s/ Gary Riccio
Chief Executive Officer